MeSH tree: C04.557.470.200.025.390
The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma ...
Jun 19, 2026
0
7
Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved by the Food and Drug Administration to treat some patients with earlier-stage kidney cancers in ...
Jun 16, 2026
0
4
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component ...
Jun 15, 2026
0
3
An experimental drug combination may help overcome treatment resistance in advanced kidney cancer, according to early results from a first-in-human clinical trial led by Mayo Clinic researchers.
Jun 5, 2026
0
3
Researchers at Trinity have found that a largely overlooked form of cancer evolution, which drives aggressive disease and poor patient outcomes, is far more widespread than previously thought. Comparing chromosome patterns ...
Jun 2, 2026
0
4
A new PET tracer targeting carbonic anhydrase IX (CAIX) has demonstrated exceptional sensitivity and high tumor-to-background contrast in detecting clear cell renal cell carcinoma (ccRCC), according to early clinical research. ...
Jun 1, 2026
0
3
A new Phase I clinical trial provides proof of concept for a potential therapy for treatment-resistant cancers, particularly kidney cancer. In the new study, published in Cell Reports Medicine, researchers tested a novel ...
May 14, 2026
0
48
Today, small kidney tumors are most often treated with a minor operation in which all or part of the kidney is removed. However, in many cases, these small tumors can be treated with targeted cryotherapy, which destroys the ...
Mar 5, 2026
0
7
The Y chromosome is among the smallest in the human body and carries the fewest genes. Researchers are paying renewed attention to its role in cancer—specifically, what happens when it vanishes.
Mar 2, 2026
0
8
Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when treated with an oral combination ...
Mar 2, 2026
0
7
